Different NF-κB activation characteristics of human respiratory syncytial virus subgroups A and B

Microbial Pathogenesis

Volumn 52, Issue 3, 2012, Pages 184-191

  Wu, Weining ^a   Macdonald, Andrew ^a   Hiscox, Julian A ^a   Barr, John N ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Activation; NF kappaB; RelA; Respiratory; Syncytial; Virus

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IMMUNOMODULATION; MOLECULAR EVOLUTION; NONHUMAN; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS SUBGROUP A; RESPIRATORY SYNCYTIAL PNEUMOVIRUS SUBGROUP B; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TITRATION;

AGED; CELLS, CULTURED; HUMANS; INFANT; NF-KAPPA B; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEROTYPING;

CERCOPITHECINE HERPESVIRUS 1; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS; PARAMYXOVIRIDAE; SUBGROUP A; SUBGROUP B;

EID: 84862825013     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2011.12.006     Document Type: Article

References (51)

1. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. NEngl J Med 2005, 352:1749-1759.
2. Hall C.B. Respiratory syncytial virus and parainfluenza virus. NEngl J Med 2001, 344:1917-1928.
3. Hall C.B., Powell K.R., MacDonald N.E., Gala C.L., Menegus M.E., Suffin S.C., et al. Respiratory syncytial viral infection in children with compromised immune function. NEngl J Med 1986, 315:77-81.
4. Becker S., Reed W., Henderson F.W., Noah T.L. RSV infection of human airway epithelial cells causes production of the beta-chemokine RANTES. Am J Physiol 1997, 272:L512-L520.
5. Fiedler M.A., Wernke-Dollries K., Stark J.M. Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. Am J Physiol 1995, 269:L865-L872.
6. Garofalo R., Sabry M., Jamaluddin M., Yu R.K., Casola A., Ogra P.L., et al. Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal inflammation. JVirol 1996, 70:8773-8781.
7. Noah T.L., Becker S. Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line. Am J Physiol 1993, 265:L472-L478.
8. Olszewska-Pazdrak B., Casola A., Saito T., Alam R., Crowe S.E., Mei F., et al. Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. JVirol 1998, 72:4756-4764.
9. Tian B., Zhang Y., Luxon B.A., Garofalo R.P., Casola A., Sinha M., et al. Identification of NF-kappaB-dependent gene networks in respiratory syncytial virus-infected cells. JVirol 2002, 76:6800-6814.
10. Zhang Y., Luxon B.A., Casola A., Garofalo R.P., Jamaluddin M., Brasier A.R. Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. JVirol 2001, 75:9044-9058.
11. Arnold R., Humbert B., Werchau H., Gallati H., Konig W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology 1994, 82:126-133.
12. Garofalo R.P., Haeberle H. Epithelial regulation of innate immunity to respiratory syncytial virus. Am J Respir Cell Mol Biol 2000, 23:581-585.
13. Adhikari A., Xu M., Chen Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007, 26:3214-3226.
14. Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006, 210:171-186.
15. Bowie A.G., Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008, 8:911-922.
16. Rahman M.M., McFadden G. Modulation of NF-kappaB signalling by microbial pathogens. Nat Rev Microbiol 2011, 9:291-306.
17. Beg A.A., Baldwin A.S. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev 1993, 7:2064-2070.
18. Henkel T., Machleidt T., Alkalay I., Kronke M., Ben-Neriah Y., Baeuerle P.A. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 1993, 365:182-185.
19. Xiao G., Harhaj E.W., Sun S.C. Domain-specific interaction with the I kappa B kinase (IKK) regulatory subunit IKK gamma is an essential step in tax-mediated activation of IKK. JBiol Chem 2000, 275:34060-34067.
20. Zamanian-Daryoush M., Mogensen T.H., DiDonato J.A., Williams B.R. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol 2000, 20:1278-1290.
21. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62.
22. Chen L.F., Williams S.A., Mu Y., Nakano H., Duerr J.M., Buckbinder L., et al. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005, 25:7966-7975.
23. Sasaki C.Y., Barberi T.J., Ghosh P., Longo D.L. Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. JBiol Chem 2005, 280:34538-34547.
24. Yoboua F., Martel A., Duval A., Mukawera E., Grandvaux N. Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta. JVirol 2010, 84:7267-7277.
25. Bitko V., Velazquez A., Yang L., Yang Y.C., Barik S. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology 1997, 232:369-378.
26. Fiedler M.A., Wernke-Dollries K., Stark J.M. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells. JVirol 1996, 70:9079-9082.
27. Jamaluddin M., Garofalo R., Ogra P.L., Brasier A.R. Inducible translational regulation of the NF-IL6 transcription factor by respiratory syncytial virus infection in pulmonary epithelial cells. JVirol 1996, 70:1554-1563.
28. Liu P., Li K., Garofalo R.P., Brasier A.R. Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-I{middle dot}NF- kappa B-inducing kinase signaling pathway. JBiol Chem 2008, 283:23169-23178.
29. Mastronarde J.G., He B., Monick M.M., Mukaida N., Matsushima K., Hunninghake G.W. Induction of interleukin (IL)-8 gene expression by respiratory syncytial virus involves activation of nuclear factor (NF)-kappa B and NF-IL-6. JInfect Dis 1996, 174:262-267.
30. Haeberle H.A., Takizawa R., Casola A., Brasier A.R., Dieterich H.J., Van Rooijen N., et al. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. JInfect Dis 2002, 186:1199-1206.
31. Jamaluddin M., Casola A., Garofalo R.P., Han Y., Elliott T., Ogra P.L., et al. The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. JVirol 1998, 72:4849-4857.
32. Spann K.M., Tran K.C., Collins P.L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. JVirol 2005, 79:5353-5362.
33. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
34. Arnold R., Konig B., Werchau H., Konig W. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 2004, 330:384-397.
35. Reimers K., Buchholz K., Werchau H. Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B. Virology 2005, 331:260-268.
36. Mufson M.A., Orvell C., Rafnar B., Norrby E. Two distinct subtypes of human respiratory syncytial virus. JGen Virol 1985, 66(Pt 10):2111-2124.
37. Hall C.B., Walsh E.E., Schnabel K.C., Long C.E., McConnochie K.M., Hildreth S.W., et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. JInfect Dis 1990, 162:1283-1290.
38. Hendry R.M., Pierik L.T., McIntosh K. Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987. JInfect Dis 1989, 160:185-190.
39. Peret T.C., Hall C.B., Schnabel K.C., Golub J.A., Anderson L.J. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. JGen Virol 1998, 79(Pt 9):2221-2229.
40. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. JInfect Dis 1991, 163:464-469.
41. White L.J., Waris M., Cane P.A., Nokes D.J., Medley G.F. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol Infect 2005, 133:279-289.
42. Zlateva K.T., Vijgen L., Dekeersmaeker N., Naranjo C., Van Ranst M. Subgroup prevalence and genotype circulation patterns of human respiratory syncytial virus in Belgium during ten successive epidemic seasons. JClin Microbiol 2007, 45:3022-3030.
43. Hendry R.M., Burns J.C., Walsh E.E., Graham B.S., Wright P.F., Hemming V.G., et al. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. JInfect Dis 1988, 157:640-647.
44. Taylor C.E., Morrow S., Scott M., Young B., Toms G.L. Comparative virulence of respiratory syncytial virus subgroups A and B. Lancet 1989, 1:777-778.
45. Power U.F. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. JClin Virol 2008, 41:38-44.
46. Ueba O. Respiratory syncytial virus. I. Concentration and purification of the infectious virus. Acta Med Okayama 1978, 32:265-272.
47. McKimm-Breschkin J.L. Asimplified plaque assay for respiratory syncytial virus-direct visualization of plaques without immunostaining. JVirol Methods 2004, 120:113-117.
48. Algarte M., Nguyen H., Heylbroeck C., Lin R., Hiscott J. IkappaB-mediated inhibition of virus-induced beta interferon transcription. JVirol 1999, 73:2694-2702.
49. Bitko V., Barik S. Persistent activation of RelA by respiratory syncytial virus involves protein kinase C, underphosphorylated IkappaBbeta, and sequestration of protein phosphatase 2A by the viral phosphoprotein. JVirol 1998, 72:5610-5618.
50. Bose S., Kar N., Maitra R., DiDonato J.A., Banerjee A.K. Temporal activation of NF-kappaB regulates an interferon-independent innate antiviral response against cytoplasmic RNA viruses. Proc Natl Acad Sci U S A 2003, 100:10890-10895.
51. Gaunt E.R., Jansen R.R., Poovorawan Y., Templeton K.E., Toms G.L., Simmonds P. Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus. PLoS One 2011, 6:e17427.